Medolife Rx, Inc., a majority owned subsidiary of Quanta, Inc. announced In a recent study, a total of 400 patients in the Dominican Republic - where, a majority tested positive for COVID-19, and a small portion were COVID-19 symptomatic even though they tested negative for COVID-19 - reported a 100 percent improvement in symptoms after being administered Escozine®.
BURBANK, CA / ACCESSWIRE / January 27, 2021 / Medolife Rx, Inc., (“Medolife”) a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA) today announced In a recent study, a total of 400 patients in the Dominican Republic - where, a majority tested positive for COVID-19, and a small portion were COVID-19 symptomatic even though they tested negative for COVID-19 - reported a 100 percent improvement in symptoms after being administered Escozine®. Many of the patients participating in the study reported severe COVID-19 symptoms, such as difficulty breathing, pain and high fever, which Escozine® was able to relieve within 5 days of treatment. Even patients under ventilators were discharged within days, thanks to this novel product. Located in Santo Domingo, Dominican Republic, The Cruz Jiminian Clinic has carried out this ongoing study since August 2020, and has reported 0 COVID-19 related deaths after the clinic began administering Escozine®. Escozine®, produced by Medolife Rx, Inc., (“Medolife”), is a therapeutic consisting of small molecule peptides derived from a specific species of scorpions, Rhopalurus princeps, endemic to the Dominican Republic. After the successful study, Escozine® is on fast-track to be registered with the Ministry of Health in the Dominican Republic in Q1 2021. Medolife also submitted the study data to the US FDA, which is currently under review for permission to repeat the clinical trial in the United States. In addition to supporting the recovery of COVID-19 patients, Escozine® was registered and certified for cancer treatment by the Ministry of Health in the Dominican Republic in 2010.
“The data proving the efficacy that Escozine has on a multitude of improved patient parameters is consistent with the rapid symptom relief I experienced while on site,” said Dr. Annabelle Morgan, Cell and Developmental Biologist and one of Medolife’s leading scientists. She noted, “What is even more astonishing is that 100% of patients tested negative for COVID-19 within 5-10 days of treatment.”
“More importantly, all COVID-19 healthcare workers, including physicians and nurses, who took Escozine as a preventative, never tested positive” said Dr. Khalid Matalka, another leading scientist at Medolife, specializing in Cancer Therapy and Immunology. “The clinical trial results indicate that Escozine could be used as monotherapy or in combination with standard therapies against COVID-19, which will accelerate the healing from the virus. Besides, observations revealed that Escozine could be used as prevention from the COVID-19 infection.”
Scorpion Venom Most Expensive Liquid in the World
From treating cancer to pain management to fighting viral infections, this unique peptide has a vast range of therapeutic applications. In the last decade, a growing interest from Big Pharma companies has caused an increase in the liquid’s value: costing $39 million per gallon.
Medolife’s Dominican Republic Scorpion Reservation is one of the largest breeding grounds for scorpions on earth. Combined with the company’s more than 15 years of research, Medolife is positioned to continue developing groundbreaking formulas and pharmaceutical-grade medications for consumer use.
Pharma’s Growing Interest in Scorpion Peptide-Based Therapeutics
Venom has been studied for therapeutic uses for decades. In 2015, the European FP7 Venomics Project studied over 200 animal species worldwide for venom-to-drug development.
Currently, six peptide drugs on the market are derived from venoms, and the pharmaceutical industry has demonstrated a growing interest in these naturally derived therapeutics. The first venom-derived drug, Captopril, was developed by Bristol-Myers Squibb. The drug, derived from snake venom, was approved for use in the 1980s to treat high blood pressure.
Snail venom was used in the development of Prialt®, which is used to treat pain. Also, Byetta®, used to treat type 2 diabetes, was derived from a lizard.
How Venom-Based Drugs Work
The Rhopalurus princeps venom contains a small molecular peptide that can pass through the blood-brain barrier in the body. Four small molecular peptides in the venom can attack various diseases in humans. To do this, it blocks small‐conductance chloride, sodium, potassium and calcium ion channels, and it also binds preferentially to abnormal and cancerous cells, leaving the normal cells intact. Medolife holds exclusive rights to the Rhopalurus princeps scorpion per the agreement signed with the Ministry of Environment and Natural Resources of the Dominican Republic.
About Medolife:
Medolife Rx, Inc. is a Wyoming corporation, founded by Dr. Arthur Mikaelian, a pioneer of polarization technology, which has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it. Dr. Mikaelian’s technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky. He also earned an MBA from the University of Bologna in Italy. You can find more about Medolife at: http://medolife.com/
About Quanta:
Quanta, Inc. (“Quanta”) utilizes a cutting-edge technology platform that applies advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta’s mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The established resonance theory behind polarization process used by Quanta has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Quanta has the opportunity to upend how commercial products are made and the benefits from them. Already, we see multitrillion dollar global industries benefiting from the technology used by Quanta. You can find more about Quanta at: https://buyquanta.com/.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company’s expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management’s goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “we believe,” “we intend,” “may,” “will,” “should,” “could,” and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company’s filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Phil Sands
https://ir.buyquanta.com/
818-659-8052
SOURCE: QUANTA, INC.
View source version on accesswire.com:
https://www.accesswire.com/626095/Medolifes-Therapeutic-Scorpion-Peptide-Proves-Successful-in-Treating-COVID-19-Patients-in-Dominican-Republic-Study
